Hypertension Diagnostics Stock Current Valuation
| HDIIDelisted Stock | USD 0 0.0008 38.10% |
Valuation analysis of Hypertension Diagnostics helps investors to measure Hypertension Diagnostics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Hypertension Diagnostics' price fluctuation is very steady at this time. Calculation of the real value of Hypertension Diagnostics is based on 3 months time horizon. Increasing Hypertension Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Hypertension Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Hypertension Pink Sheet. However, Hypertension Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0029 | Real 0.002768 | Hype 0.003625 | Naive 0.001735 |
The intrinsic value of Hypertension Diagnostics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Hypertension Diagnostics' stock price.
Estimating the potential upside or downside of Hypertension Diagnostics helps investors to forecast how Hypertension pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Hypertension Diagnostics more accurately as focusing exclusively on Hypertension Diagnostics' fundamentals will not take into account other important factors: Hypertension Diagnostics Company Current Valuation Analysis
Hypertension Diagnostics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Hypertension Diagnostics Current Valuation | 5.26 M |
Most of Hypertension Diagnostics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hypertension Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Hypertension Diagnostics has a Current Valuation of 5.26 M. This is 99.98% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 99.97% higher than that of the company.
Hypertension Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hypertension Diagnostics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hypertension Diagnostics could also be used in its relative valuation, which is a method of valuing Hypertension Diagnostics by comparing valuation metrics of similar companies.Hypertension Diagnostics is currently under evaluation in current valuation category among its peers.
Hypertension Fundamentals
| Return On Asset | 3.0E-4 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.0002 % | ||||
| Current Valuation | 5.26 M | ||||
| Shares Outstanding | 52.39 M | ||||
| Price To Earning | (0.03) X | ||||
| Price To Sales | 0.15 X | ||||
| Revenue | 3.79 M | ||||
| Gross Profit | 954.47 K | ||||
| EBITDA | 72.29 K | ||||
| Net Income | (125.39 K) | ||||
| Cash And Equivalents | 5.66 K | ||||
| Total Debt | 4.69 M | ||||
| Current Ratio | 0.52 X | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (389.28 K) | ||||
| Earnings Per Share | (0) X | ||||
| Beta | -0.92 | ||||
| Market Capitalization | 730.42 K | ||||
| Total Asset | 1.28 M | ||||
| Retained Earnings | (30.68 M) | ||||
| Working Capital | (857 K) | ||||
| Current Asset | 277 K | ||||
| Current Liabilities | 1.13 M | ||||
| Z Score | -31.6 | ||||
| Net Asset | 1.28 M |
About Hypertension Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hypertension Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hypertension Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hypertension Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Hypertension Pink Sheet
If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |